Women are drastically underrepresented in HIV cure research studies. The need for a cure is critical, but will the search for HIV cure strategies include women?
Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.
A report on three other cases of HIV-infected individuals receiving stem cell transplants indicates the likely role that CCR5 mutation plays in HIV remission or cure.
A review of HIV drugs in development that summarizes the most exciting new research over the previous year.
Scientists Hone in on the Best Way to Expose HIV Hidden in the Viral Reservoir, a Crucial Step Toward an Eventual Cure
Researchers at the University of North Carolina identified a better dosing strategy for a drug that exposes HIV hiding inside the body's viral reservoir, according to a new study.
Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.
Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.
Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?
Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.
Gilead Sciences has submitted a new drug application to the U.S. FDA for a single tablet fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).